Compare JJSF & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | ODTX |
|---|---|---|
| Founded | 1971 | 2021 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1995 | 2025 |
| Metric | JJSF | ODTX |
|---|---|---|
| Price | $85.40 | $19.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $110.50 | $35.33 |
| AVG Volume (30 Days) | 188.9K | ★ 228.1K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $42.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $15.10 |
| 52 Week High | $98.63 | $29.05 |
| Indicator | JJSF | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.67 | 46.77 |
| Support Level | $77.64 | $15.73 |
| Resistance Level | $88.12 | $19.60 |
| Average True Range (ATR) | 2.13 | 1.35 |
| MACD | 0.58 | 0.31 |
| Stochastic Oscillator | 90.43 | 65.85 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.